# HugoScore CAIHL Draft Report: Abridge Status: Draft for human review Generated: 2026-06-08 Last reviewed: 2026-06-12 Review method: Deep public-source refresh of official product pages, privacy policy, trust center, health-system patient explainers, and published studies. On 2026-06-12, a high-scrutiny factual audit re-verified every cited source directly and added litigation and platform-expansion findings (see `audits/hugoscore-audit-abridge-2026-06-12.md`). No vendor interview or hands-on deployment testing. Service: Abridge Vendor: Abridge AI, Inc. Category: Ambient scribe / clinical documentation AI ## Executive Summary Abridge is an enterprise ambient documentation platform that turns patient-clinician conversations into clinician-reviewed notes. As of mid-2026 it has expanded well beyond note drafting: point-of-care clinical decision support with NEJM/JAMA evidence, order support, coding and HCC capture, real-time prior authorization with Availity, and payer and life-sciences integrations. The vendor describes the clinical conversation as a "connective layer between providers, payers and pharma companies." From a CAIHL perspective, Abridge is health AI that affects patients, but it is not patient-directed. It may indirectly support patient agency when it reduces clinician distraction and produces notes patients can review, but the patient does not control the tool, usually cannot access the transcript or audio, and does not set the deployment rules. Two pending California lawsuits (against Sharp HealthCare, and against Sutter Health and MemorialCare) allege that visits were recorded without informed consent at Abridge customer deployments. Those allegations are unproven, but they show that deployment-level consent practice cannot be assumed from policy language. Agency posture: Mixed Confidence: Medium draft, deployment-specific ## Evidence - Abridge homepage: https://www.abridge.com/ - Abridge Privacy Policy (updated 2025-08-22): https://www.abridge.com/privacy - Abridge Trust Center: https://trust.abridge.com/ - Abridge Clinical Decision Support product page: https://www.abridge.com/cds - Abridge/Availity prior-authorization announcement (2026-01-12): https://www.abridge.com/press-release/abridge-availity-collaboration-announcement - Abridge keynote, patient-centered clinician intelligence platform with Aetna, Eli Lilly, Nvidia (2026-06-11): https://www.businesswire.com/news/home/20260611779141/en/ - CPCMG patient explainer (updated 2026-03-12): https://healthhub.cpcmg.net/docs/ambient-documentation-charting-abridge-privacy-security - UChicago Medicine patient explainer: https://www.uchicagomedicine.org/forefront/patient-care/ai-ambient-clinical-documentation-what-to-know - JAMA Network Open Sutter evaluation (Stults et al., 2025;8(5):e258614): https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833433 - JAMIA Open/KUMC study (8(1), Feb 2025): https://pubmed.ncbi.nlm.nih.gov/39991073/ - Patient-experience study, Applied Clinical Informatics (Jan 2026): https://pubmed.ncbi.nlm.nih.gov/41760358/ - Consent lawsuit coverage, Sharp HealthCare (filed 2025-11-26): https://www.kpbs.org/news/health/2025/12/11/lawsuit-claims-sharp-healthcare-secretly-recorded-exam-room-conversations-without-patient-consent - Consent lawsuit coverage, Sutter Health/MemorialCare (filed 2026-04-08): https://www.techtarget.com/healthtechsecurity/news/366641717/Sutter-Health-MemorialCare-face-class-action-lawsuit-over-AI-scribe-use ## Mixed HugoScore Profile - Who does this AI serve? Institutional / clinician-mediated. Abridge is purchased by health systems and used by clinicians; the vendor now also markets payer and life-sciences integrations, with Eli Lilly as a strategic investor. - Can patients tell AI is involved? Partial. Some deployments publish explainers and require permission at every visit, but pending lawsuits allege other deployments recorded visits without clear notice. - Can patients meaningfully choose? Partial. CPCMG and UChicago Medicine say patients can decline with no change in care; pending litigation alleges consent was not sought in practice at other systems. - Can patients correct or challenge what the AI produces? Partial. Patients may see final notes through open notes (UChicago documents a correction route by portal message), but CPCMG confirms patients do not receive copies of recordings or transcripts. - Does it help patients understand or act? Indirectly. Abridge is not patient-directed, but better clinician attention and more complete open notes may help in strong deployments. ## Patient Agency Interpretation Abridge can support patient agency when it makes AI use visible, optional, clinician-reviewed, and correctable through open-note workflows. Its CAIHL risk is structural and growing: the same audio stream a patient is told supports their visit note now also feeds coding and risk-adjustment capture, prior-authorization workflows, care-gap closure, and clinical-trial identification. The vendor's own framing, the conversation as a connective layer to payers and pharma, confirms that institutional legibility is expanding faster than patient control. The pending consent lawsuits, whatever their outcome, mark the gap between deployment policy and deployment practice as a live, documented question rather than a hypothetical. ## Publication Recommendation Ready for human review as a refreshed draft profile. Do not publish as final until consent, refusal, retention, transcript/audio access, correction, and error evidence are verified across multiple deployments, and until the axis position is re-weighed against the payer/pharma platform expansion and the course of the pending litigation. Litigation must remain framed as allegations unless courts rule.